Lamivudine Tablet, Film Coated
NDC Package 60505-3250-6
Package Information
Lamivudine tablets is (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)].The following points should be considered when initiating therapy with lamivudine tablets (HBV):Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus.Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. This formulation utilizes a tablet, film coated delivery system. Marketed by Apotex Corp., this product is identified by NDC 60505-3250 and is authorized under FDA application ANDA202941.
Identification & Billing
- RxCUI: 205328 - lamiVUDine 100 MG Oral Tablet
- RxCUI: 205328 - lamivudine 100 MG Oral Tablet
- RxCUI: 205328 - 3TC 100 MG Oral Tablet
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 60505 - Apotex Corp.
- 60505-3250 - Lamivudine
- 60505-3250-6 - 60 TABLET, FILM COATED in 1 BOTTLE
- 60505-3250 - Lamivudine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 60505-3250-6 identifies a specific commercial package of 60 tablet, film coated in 1 bottle of Lamivudine, a human prescription drug labeled by Apotex Corp.. This tablet, film coated is formulated for oral use and contains lamivudine as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Apotex Corp. on January 03, 2014. The current certification is valid through December 31, 2027.
How is this Apotex Corp. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 60505325006. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.